Merck's sacituzumab tirumotecan meets dual primary endpoints in Phase 3 TroFuse-005 endometrial cancer study at ESMO 2026

Merck announced results from two late-stage clinical studies in advanced or recurrent endometrial cancer at ESMO 2026. In the Phase 3 TroFuse-005 study, developed with Kelun-Biotech, sacituzumab tirumotecan met its dual primary endpoints in patients previously treated with platinum-based chemotherapy and immunotherapy.

Detected & updated continuously · Source: Nebula